Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.51 |
| ▸ | CA1 | P00915 | 3/20 | 0.51 |
| ▸ | CA2 | P00918 | 3/20 | 0.51 |
| ▸ | CA7 | P43166 | 3/20 | 0.51 |
| ▸ | CA9 | Q16790 | 3/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.51 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 2/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL642332 | 0.85 | CA12 (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2653764 | 0.84 | LMNA (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL643132 | 0.80 | KDM4E (0.45) | CA12CA1CA2CA7CA9 | |
| SCHEMBL18585733 | 0.79 | KDM4E (0.45) | CA12CA1CA2CA7CA9 | |
| SCHEMBL642064 | 0.78 | CA12 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL18585198 | 0.78 | PARP1 (0.38) | CA2PTPN11AKR1B1CYP1A2MEN1 | |
| SCHEMBL18585262 | 0.78 | KDM4E (0.37) | AKR1B1CYP1A2MEN1KMT2ANPC1 | |
| SCHEMBL643651 | 0.77 | CA12 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8122290 | 0.75 | CA12 (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10643179 | 0.75 | CA12 (0.50) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2463283-B1 | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases | PFIZER PROD INC (US) | 2014-06-11 | — | — | EP | disclosed |
| US-8735396-B2 | Benzofuranyl derivatives | PFIZER INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735396-B2 | Benzofuranyl derivatives | PFIZER INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735396-B2 | Benzofuranyl derivatives | PFIZER INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20130252973-A1 | Benzofuranyl Derivatives | PFIZER INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252973-A1 | Benzofuranyl Derivatives | PFIZER INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252973-A1 | Benzofuranyl Derivatives | PFIZER INC. (US) | 2013-09-26 | — | — | US | disclosed |
| EP-2406253-B1 | BENZOFURANYL DERIVATIVES USED AS GLUCOKINASE INHIBITORS | PFIZER (US) | 2013-07-03 | — | — | EP | disclosed |
| EP-2406253-B1 | BENZOFURANYL DERIVATIVES USED AS GLUCOKINASE INHIBITORS | PFIZER (US) | 2013-07-03 | — | — | EP | disclosed |
| EP-2604604-A1 | Benzofuranyl derivatives used as glucokinase inhibitors | Pfizer Inc (US) | 2013-06-19 | — | — | EP | disclosed |
| WO-2010103437-A1 | BENZOFURANYL DERIVATIVES USED AS GLUCOKINASE INHIBITORS | PFIZER INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010103437-A1 | BENZOFURANYL DERIVATIVES USED AS GLUCOKINASE INHIBITORS | PFIZER INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| US-20100234285-A1 | Benzofuranyl Derivatives | PFIZER INC | 2010-09-16 | — | — | US | disclosed |
| US-20100234285-A1 | Benzofuranyl Derivatives | PFIZER INC | 2010-09-16 | — | — | US | disclosed |
| EP-2010520-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | Pfizer Products Incorporated (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| WO-2007122482-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007122482-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234285-A1 | Benzofuranyl Derivatives | GCK, GCKR, GALK1 | CA12 4586/4885CA1 4522/4885CA2 2065/4885 |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | GCK, GCKR, HK1 | CA12 3102/4885CA1 1547/4885CA2 574/4885 |
| US-20130252973-A1 | Benzofuranyl Derivatives | GCK, GCKR, GALK1 | CA12 4586/4885CA1 4522/4885CA2 2065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.